Subscribe To
Oculis to present a late-breaking abstract at the 23rd euretina congress on positive phase 3 stage 1 diamond trial results for diabetic macular edema
ZUG, Switzerland, and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharm...
October 5, 2023, 6:30 am
Novartis to present new oncology data at esmo 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology...
October 5, 2023, 1:15 am
Pharvaris to present at the ciic fall 2023 conference
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor a...
October 4, 2023, 7:34 am
Beyond cancer™ selected to present proffered posters discussing data from the uno therapy program at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that i...
October 4, 2023, 7:30 am
Genentech to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus®...
October 2, 2023, 1:00 am
Roche to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd
Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine ki...
October 2, 2023, 1:00 am
Investigation of morphic holding, inc. (morf) announced by holzer & holzer, llc
ATLANTA, Sept. 29, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Morphic Holding, Inc. (“Morphic” or “the Company”) ...
September 29, 2023, 9:51 pm
Exagen announces acceptance of multiple abstracts at acr 2023 annual meeting
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced to...
September 28, 2023, 8:05 pm
Onconova therapeutics to present a late-breaking abstract on rigosertib at the 2023 eadv congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage bi...
September 28, 2023, 12:00 pm
Brainstorm shares plunge 56% after fda advisers reject als cell therapy
Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral scle...
September 28, 2023, 9:46 am
Candel therapeutics announces three abstracts accepted for poster presentations at sitc 2023 annual meeting
One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical tria...
September 27, 2023, 1:40 pm
Coherus announces three presentations at the 38th annual meeting of the society for immunotherapy of cancer (sitc)
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three...
September 27, 2023, 1:10 pm
Travere therapeutics to present abstracts at the 17th international symposium on iga nephropathy (iigann 2023)
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will pr...
September 26, 2023, 4:30 pm
Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...
September 22, 2023, 9:30 pm
Morphic to present positive emerald-1 phase 2a data for morf-057 in patients with moderate to severe ulcerative colitis in abstract for uegw 2023
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-...
September 22, 2023, 5:30 pm
Kiora pharmaceuticals to present topline results from the abacus study at american academy ophthalmology (aao); phase 1b study evaluating kio-301 in retinitis pigmentosa
Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that r...
September 14, 2023, 7:01 am
Molson coors: tap's resilience and revenue expansion plan
Molson Coors Beverage reported strong financial results in 2Q23, driven by increased marketing spend and momentum in core beer brands. The company pla...
September 12, 2023, 10:07 am
Eagle pharmaceuticals to present cal02 trial in progress at the 2023 asm/escmid joint conference on drug development to meet the challenge of antimicrobial resistance
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence fact...
September 11, 2023, 6:50 am
Microbot medical gains global recognition; professor vincent vidal to present an abstract on the liberty® robotic surgical system at cirse 2023
The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies The presentation follows succe...
September 8, 2023, 10:02 am
Harpoon therapeutics abstract for hpn217 accepted for poster presentation at the 20th international myeloma society annual meeting
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company d...
September 6, 2023, 11:30 am